Utilizing these limits, data from Monica studies, or observations of comparable reliability, were used to map out the international situation [1]. In Europe, the Scandinavian figures are lowest, being about 10% in middle-aged subjects in Sweden, Norway and Denmark, whilst Finland shows twice this prevalence. The figures on the western part of the continent, including England, are about 15–20%. In the east, a much worse prevalence was observed, approaching 70% amongst women in Lithuania and Russia. In the US the prevalance is close to 30%, with dramatic peaks in minorities such as blacks, and some American Indian tribes. In Australian aboriginies and the population on certain Pacific inlands, the prevalance approaches 100%. There are clear indications of rising prevalence in several countries, including Sweden. In addition, in developing countries such as in the Carribean area, South America and South-East Asia, obesity is now also becoming more common. In China the prevalance is low, but also rising. In absolute numbers a 1% increase in China corresponds to many millions of obese subjects, in a population which seems particularly vulnerable to diabetes (type 2)[1]. The global situation is thus alarming, and countermeasures are indicated. Treatment can only be offered to those with severe comorbidities due to the magnitude of the problem. Prevention must be the strategy selected. The WHO, with the assistance of a number of professional and lay organizations, will advise and lead such efforts.